Published in Vaccine Weekly, December 26th, 2001
Potentially even more important to the field of vaccine research is the finding that, even after repeat administration, only minimal immune responses were developed against the delivery peptides used by the L.E.A.P.S. technology (called a T-cell binding ligand), while strong immune responses were elicited against the HIV portion of the peptide. This may indicate that, unlike other...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly